Myocarditis and anti-Covid vaccines: the risk exists but remains weak with Pfizer and Moderna, according to the ANSM

In the framework of the enhanced surveillance system for vaccines against Covid-19, EPI-PHARE (groupement d’intérêt scientifique ANSM-Cnam) has conducted a new pharmaco-epidemiological study on the risk of myocarditis after a vaccination par a vaccine mRNA (Comirnaty or Spikevax).

An increased risk mais faible. There is indeed a risk of myocarditis after the first booster dose (troisième dose) but it is weaker than after the second dose and decreases with the lengthening of the delay between successive doses, according to a study by the National Agency of santé du médicament, published on July 22.

Des cas plus importants chez les hommes de moins de moins de 30 ani

A myocarditis is an inflammation of the myocardium, le tissu musculaire du cœur. Viral infections, like Covid, have frequent causes of myocarditis, which can lead to hospitalization, heart failure or sudden death. Myocarditis is also recognized as a very rare adverse effect of mRNA vaccines (Pfizer or Moderna) by the Agence Européenne du Médicament.

“The excess of cases of myocarditis associated with the third dose is globally estimated at 0.25 cases per 100,000 doses of the Comirnaty vaccine and 0.29 cases per 100,000 doses of the Spikevax vaccine, corresponding to 1 case of myocarditis attributable to vaccination pour l’administration of 398,000 three doses of Comirnaty and of 340,000 treis doses of Spikevax”, indicates encore l’ANSM.

And to conclude: “Les excès de cas les plus importants ont été observés chez hommes de moins de 30 ans, avec un maximum de 1.2 cas pour 100 000 troisièmes doses de Comirnaty, ce qui correspond à 1 cas de myocardite pour 87 000 three doses”.

A previous study by EPI-PHARE, the results of which have not been published in the journal Nature Communications, showed that there was a risk of myocardial infarction in the week after vaccination against Covid-19 by mRNA vaccines, in particular. after the second dose of Spikevax vaccine in men and women aged 12 to 50 years.

This previous study also confirmed the favorable clinical evolution of the case of myocarditis.

How to treat myocarditis?

In the case of myocarditis, hospitalization is necessary and lasts “au moins 48 heures”, explains Dre Manzo-Silberman à Doctissimo. “When on voit qu’il ya une atteinte du muscle cardiaque, c’est une hospitalization en soins intensifs.” The myocardium is a disease that must especially detect possible complications. “Il faut être sûr que ce ne soit pas un infarctus évolutif, qu’il n’y ait pas une artère à aller déboucher”, ajoute-t-il à nos frères.

According to the cardiology service of the CHUV, the treatment is mostly composed of anti-inflammatory drugs and pain relievers (for chest pains).

Leave a Comment